8-K: Neuraxis Reports Preliminary Q3 2025 Financials

Neuraxis, Inc. disclosed preliminary unaudited financial results for the third quarter and nine months ended September 30, 2025, showing increased year-to-date sales but a quarterly operating loss.

Summary

• Neuraxis, Inc. (the Company) issued preliminary unaudited financial results for the three and nine months ended September 30, 2025.
• As of September 30, 2025, cash and cash equivalents are expected to be approximately $4.4 million.
• For the three months ended September 30, 2025, net sales are expected to be approximately $0.8 million, gross profits approximately $0.7 million, and operating loss approximately $2.1 million.
• For the nine months ended September 30, 2025, net sales are expected to be approximately $2.6 million, an increase from approximately $1.9 million for the nine months ended September 30, 2024.
• These estimates are preliminary, unaudited, and subject to change as the Company finalizes its financial statements.

Sentiment

Score: 4

Explanation: While year-to-date sales show growth, the significant quarterly operating loss and the preliminary, unaudited nature of all figures introduce uncertainty and potential for negative revisions, leading to a cautious sentiment.

Positives

• Net sales for the nine months ended September 30, 2025, increased to approximately $2.6 million, up from approximately $1.9 million for the same period in 2024, representing a growth of approximately 36.8%.

Negatives

• The Company expects an operating loss of approximately $2.1 million for the three months ended September 30, 2025.
• Cash and cash equivalents are approximately $4.4 million as of September 30, 2025, which may be considered low for ongoing operations and growth.

Risks

• The financial estimates provided are preliminary and unaudited, subject to significant judgments and potential material adjustments during the finalization process.
• Undue reliance should not be placed on these preliminary estimates as they may differ from the final reported amounts.
• The Company's independent registered public accounting firm has not audited, reviewed, or performed any procedures on these preliminary estimates.

Future Outlook

The Company expects to complete its financial statements for the three and nine months ended September 30, 2025, subsequent to this 8-K filing. It is possible that adjustments, potentially material, may be identified during the finalization process by the Company or its independent registered public accounting firm.

Management Comments

• The preliminary estimates have been prepared by and are the responsibility of the Company's management.

Industry Context

NA

Stakeholder Impact

• Shareholders face uncertainty due to the preliminary and unaudited nature of the financial results, which could be subject to material changes.
• Investors will be evaluating the Company's ability to manage its operating losses and cash position based on these preliminary figures.

Next Steps

• Complete the financial statement close process and finalize financial statements and accompanying notes for the three and nine months ended September 30, 2025.

Key Dates

Recommendation

The preliminary nature of the financial results, coupled with an increase in year-to-date sales but a notable quarterly operating loss, presents a mixed picture. Without audited financials, detailed explanations, or forward guidance, a seasoned investor would likely hold their position, awaiting the final, audited report for a more comprehensive assessment of the company's financial health and trajectory.

Keywords

Neuraxis, NRXS, financial results, Q3 2025, preliminary earnings, net sales, operating loss, cash equivalents, SEC filing, 8-K